Copd

/Tag:Copd

Abstract Number: Oral

DERIVATION AND VALIDATION OF A COPD READMISSION RISK PREDICTION TOOL

Background: Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of hospital readmissions in America. Over one-third of patients admitted for COPD exacerbations are readmitted within 90 days, with readmissions costing $15 billion. Medicare [...]

By | 2019-03-12T15:46:24+00:00 March 11th, 2019|Hospital Medicine 2019, Oral Presentations, Research, Technology in Hospital Medicine|Comments Off on DERIVATION AND VALIDATION OF A COPD READMISSION RISK PREDICTION TOOL

Abstract Number: 178

ASSOCIATION OF HOSPITAL READMISSION REDUCTION PROGRAM IMPLEMENTATION WITH READMISSION RATE AND MORTALITY OUTCOME IN HOSPITALIZED PATIENTS WITH ACUTE EXACERBATION OF COPD (AECOPD)

Background: Hospital Readmission Reduction Program(HRRP) implemented by CMS as part of Affordable Care Act (ACA) applies financial penalties to hospitals that have higher-than-expected readmission rates for common conditions such as AMI, pneumonia, and HF. CMS [...]

By | 2019-03-11T14:20:00+00:00 March 11th, 2019|Hospital Medicine 2019, Outcomes Research, Research|Comments Off on ASSOCIATION OF HOSPITAL READMISSION REDUCTION PROGRAM IMPLEMENTATION WITH READMISSION RATE AND MORTALITY OUTCOME IN HOSPITALIZED PATIENTS WITH ACUTE EXACERBATION OF COPD (AECOPD)

Abstract Number: 128

PREVALENCE AND PREDICTORS OF SUBOPTIMAL PIFR ACROSS GOLD STAGES: ANALYSES FROM THE REVEFENACIN PHASE 3 PROGRAM

Background: Many patients with chronic obstructive pulmonary disease (COPD) have suboptimal peak inspiratory flow rate (sPIFR) because of lung hyperinflation, hypoxemia, and muscle wasting, preventing effective use of dry powder inhalers commonly used to treat [...]

By | 2019-03-11T14:18:46+00:00 March 11th, 2019|Hospital Medicine 2019, Other, Research|Comments Off on PREVALENCE AND PREDICTORS OF SUBOPTIMAL PIFR ACROSS GOLD STAGES: ANALYSES FROM THE REVEFENACIN PHASE 3 PROGRAM

Abstract Number: 127

EFFICACY AND SAFETY OF REVEFENACIN IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS NOT AGE DEPENDENT: A POST HOC SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS

Background: Revefenacin (REV), a once-daily, long-acting muscarinic antagonist for nebulized inhalation, was recently approved for maintenance treatment of chronic obstructive pulmonary disease (COPD). We present post hoc efficacy and safety data from three phase 3 [...]

By | 2019-03-11T14:18:44+00:00 March 11th, 2019|Hospital Medicine 2019, Other, Research|Comments Off on EFFICACY AND SAFETY OF REVEFENACIN IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS NOT AGE DEPENDENT: A POST HOC SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS

HM2018 Abstract Number: 120

ASSOCIATION BETWEEN STEROID MODALITY AND LENGTH OF STAY IN ACUTE COPD EXACERBATIONS

Background: Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality, and cost with the greatest proportion incurred treating acute exacerbations of COPD (AECOPD). While guidelines recommend oral steroids for the treatment of AECOPD, [...]

By | 2018-03-19T15:44:08+00:00 March 19th, 2018|Outcomes Research, Research, Uncategorized|Comments Off on ASSOCIATION BETWEEN STEROID MODALITY AND LENGTH OF STAY IN ACUTE COPD EXACERBATIONS

HM2018 Abstract Number: 339

Revefenacin, an Investigational Long-acting Muscarinic Antagonist for Nebulization: Pooled Results of Replicate Phase 3 Trials in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Background: Currently, once-daily nebulized bronchodilator therapy is unavailable for patients with chronic obstructive pulmonary disease (COPD). Prior studies demonstrated that once-daily revefenacin (REV) doses of 88 and 175 µg produced significant bronchodilation in COPD patients. [...]

By | 2018-03-19T13:14:25+00:00 March 19th, 2018|Hospital Medicine 2018, Research, Translating Research into Practice|Comments Off on Revefenacin, an Investigational Long-acting Muscarinic Antagonist for Nebulization: Pooled Results of Replicate Phase 3 Trials in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

HM2018 Abstract Number: 216

REDUCING HOSPITAL READMISSIONS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A QUALITY IMPROVEMENT PROJECT

Background: COPD exacerbations are among the leading causes of hospital readmissions. According to the COPD Foundation, in 2013, 22% patients admitted for COPD exacerbation required readmission within 30 days of discharge. This represents a significant [...]

By | 2018-03-19T13:12:03+00:00 March 19th, 2018|Hospital Medicine 2018, Quality Improvement, Research|Comments Off on REDUCING HOSPITAL READMISSIONS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A QUALITY IMPROVEMENT PROJECT

HM2018 Abstract Number: 140

LEVERAGING LEAN TO INFORM APPLIED RESEARCH IN ACUTE CARE: A CASE STUDY TO IMPROVE COPD OUTCOMES

Background: The US healthcare system is under increasing pressure to improve value and affordability. Acute care is responsible for a large proportion of overall health costs, but the complexities and pace in this environment have [...]

By | 2018-03-19T12:54:03+00:00 March 19th, 2018|Hospital Medicine 2018, Innovations, Outcomes Research|Comments Off on LEVERAGING LEAN TO INFORM APPLIED RESEARCH IN ACUTE CARE: A CASE STUDY TO IMPROVE COPD OUTCOMES

HM2017 Abstract Number: 183

UTILITY OF POWER PLAN IN STANDARDIZING CARE OF HOSPITALIZED COPD PATIENT

Background: Several studies attest the effectiveness of physician order set, also known as Power Plan (PP) in standardizing patient care and improving outcomes. In general, PP use is suboptimal. We hypothesized that PP use in [...]

By | 2017-04-26T03:01:06+00:00 April 20th, 2017|Quality Improvement, Research Abstracts|Comments Off on UTILITY OF POWER PLAN IN STANDARDIZING CARE OF HOSPITALIZED COPD PATIENT

HM2017 Abstract Number: 76

PREDICTORS OF COPD READMISSIONS – A RETROSPECTIVE STUDY

Background: The Centers for Medicare & Medicaid Services (CMS) started penalizing hospitals with “excess” 30-day readmissions, as determined by observed-to-expected ratio, for patients discharged after treatment for an acute exacerbation of chronic obstructive pulmonary disease [...]

By | 2017-04-20T19:09:22+00:00 April 20th, 2017|Outcomes Research, Research Abstracts|Comments Off on PREDICTORS OF COPD READMISSIONS – A RETROSPECTIVE STUDY

HM2016 Abstract Number: 490

Respiratory Failure: An Uncommon Presenting Symptom in Neurologic Weakness

Case Presentation: A 75 year-old man with history of type II diabetes and hypertension presented with progressive dyspnea. Two weeks prior, he had presented with similar symptoms that were attributed to COPD due to a [...]

By | 2016-02-01T08:00:34+00:00 February 1st, 2016|Adult, Clinical Vignettes Abstracts|Comments Off on Respiratory Failure: An Uncommon Presenting Symptom in Neurologic Weakness

HM2016 Abstract Number: 360

Effect of Intravenous Route of Administration on Corticosteroid Dosage in Aecopd

Background: Consensus supports the use of corticosteroids in acute exacerbation of COPD (AECOPD), but route of administration and dosage still vary considerably. In one study comparing lower dose oral (PO) prednisone to higher dose intravenous [...]

By | 2016-02-01T08:00:34+00:00 February 1st, 2016|Research Abstracts, Value in Hospital Medicine|Comments Off on Effect of Intravenous Route of Administration on Corticosteroid Dosage in Aecopd

HM2016 Abstract Number: 135

Analyses of Real-World Treatment Patterns Among Hospitalized Chronic Obstructive Pulmonary Disease (Copd) Patients with Low Peak Inspiratory Flow: Interim Findings from a Prospective Observational Study

Background: Research suggests that COPD patients with low peak inspiratory flow rate (PIFR,

By | 2016-02-01T08:00:34+00:00 February 1st, 2016|Outcomes Research, Research Abstracts|Comments Off on Analyses of Real-World Treatment Patterns Among Hospitalized Chronic Obstructive Pulmonary Disease (Copd) Patients with Low Peak Inspiratory Flow: Interim Findings from a Prospective Observational Study

HM2016 Abstract Number: 129

Role of Early Outpatient Follow-Up Appointments on Decreasing Copd Readmission Rates

Background: Chronic Obstructive Pulmonary Disease (COPD) is the third most common cause of hospital readmission within 30 days of discharge. These readmissions increase the overall healthcare cost burden. We examined the effect of early follow-up [...]

By | 2016-02-01T08:00:34+00:00 February 1st, 2016|Outcomes Research, Research Abstracts|Comments Off on Role of Early Outpatient Follow-Up Appointments on Decreasing Copd Readmission Rates

HM2016 Abstract Number: 101

Length of Stay Is Reduced by Converting Intravenous Corticosteroids to Oral in Aecopd Hospitalizations

Background: The 2015 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend the use of systemic corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Although prior guidelines did not [...]

By | 2016-02-01T08:00:34+00:00 February 1st, 2016|Outcomes Research, Research Abstracts|Comments Off on Length of Stay Is Reduced by Converting Intravenous Corticosteroids to Oral in Aecopd Hospitalizations

HM2016 Abstract Number: 94

Confidence in Correct Inhaler Device Technique and Its Association with Health Status and Patient Satisfaction: An Analysis of Real-World Us Chronic Obstructive Pulmonary Disease (Copd) Patients

Background: Correct inhaler technique for COPD medications is essential to achieving optimum delivery into the lungs. Evidence suggests that poor technique is widespread and linked to poor efficacy and adherence. However, the direct relationship between [...]

By | 2016-02-01T08:00:34+00:00 February 1st, 2016|Outcomes Research, Research Abstracts|Comments Off on Confidence in Correct Inhaler Device Technique and Its Association with Health Status and Patient Satisfaction: An Analysis of Real-World Us Chronic Obstructive Pulmonary Disease (Copd) Patients

HM2016 Abstract Number:

Driving Down Readmissions: Evaluation of an Inter-Professional Program to Reduce Readmissions After Copd

Background: Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) is the third leading cause of readmissions and is now included in the Medicare Hospital Readmissions Reduction Program (HRRP). Our institution developed an inter-professional program aimed [...]

By | 2016-03-04T15:13:02+00:00 February 1st, 2016|Oral Presentations, Research Abstracts|Comments Off on Driving Down Readmissions: Evaluation of an Inter-Professional Program to Reduce Readmissions After Copd